Preview Mode Links will not work in preview mode

Oct 10, 2020

Proceedings from the first in a 3-part webinar series. Featuring perspectives from Drs Andrew McKenzie, Bryan P Schneider and Milan Radovich, including the following topics:

  • Part 1: Case Discussions
    • Introduction (00:00)
    • Case: A man in his mid-70s with prostate cancer (AKT1 E17k mutation) — Milan Radovich, PhD and Bryan P Schneider, MD (5:39)
    • Case: A frail woman in her early 80s with endometrial cancer (AKT mutation) — Sulfi Ibrahim, MD (7:45)
    • Case: A man in his late 50s with salivary gland head and neck squamous cell carcinoma (NTRK3-ETV6 fusion) — Andrew McKenzie, PhD (14:53)
    • Case: A man in his early 80s with bladder cancer (tumor mutational burden 67 mut/Mb) — Drs Radovich and Schneider (17:15)
    • Case: A man in his late 60s with muscle-invasive bladder cancer (PIK3CA mutation, RET amplification) — Dr Ibrahim (21:57)
    • Case: A man in his early 60s with cholangiocarcinoma (FGFR2 rearrangement) — Dr McKenzie (25:35)
  • Part 2: FDA-Approved and Guideline-Endorsed Platforms for Genomic Testing
    • Advantages and limitations of available assays (29:33)
  • Part 3: Case Discussions
    • Case: A woman in her mid-60s with glioblastoma (FGFR3-TACC3 fusion) — Drs Radovich and Schneider (39:21)
    • Case: A man in his early 80s with cancer of unknown primary (TMPRSS2-ERG fusion) — Dr Ibrahim (41:43)
    • Case: A woman in her mid-60s with metastatic breast cancer (PIK3CA, ESR1 mutations) — Dr McKenzie (48:03)
    • Case: A woman in her mid-60s with pancreatic cancer (KRAS G12C mutation) — Drs Radovich and Schneider (52:52)
    • Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung (KRAS G12C mutation) — Dr McKenzie (54:45)

CME information and select publications